Table 1.
Sex | Age (years) | Primary site | Time to liver surgery (months) | Synchronous cancer | Number of metastasis | Largest diameter (mm) | CEA at liver surgery (μg/l) | PGE2 at liver surgery (pg/ml) | HLA-A2 status | Disease-free survival (months) | Overall survival (months) | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
F | 40 | Colon | 8 | Yes | 7 | 75 | 1.426 | 205 | ND | 12 | 29 | CRD |
F | 45 | Rectum | 6 | Yes | 5 | 50 | 0.9 | 487 | Neg | 8 | AWD | |
F | 45 | Colon | 4 | Yes | 9 | 22 | 17.3 | 411 | Pos | 23 | AWD | |
F | 61 | Colon | 1 | Yes | 2 | 22 | 5.1 | 42 | Neg | 4 | AWD | |
F | 61 | Rectum | 5 | Yes | 1 | 19 | 0.9 | ND | Pos | FREE | ||
F | 63 | Colon | 13 | No | 1 | 16 | 16.6 | 602 | Pos | FREE | ||
F | 66 | Colon | 52 | No | 3 | 70 | 1.7 | 517 | Neg | 8 | FREE | |
F | 67 | Rectum | 7 | No | 1 | 17 | 3.4 | 350 | ND | FREE | ||
M | 44 | Colon | 6 | Yes | 5 | 10 | 1 | 353 | Pos | 6 | NCRD | |
M | 60 | Colon | 7 | Yes | 20a | 13a | ND | 442 | Neg | AWD | ||
M | 62 | Rectum | 2 | Yes | 1 | 25 | ND | 173 | Neg | 7 | AWD | |
M | 64 | Rectum | 11 | Yes | 3 | 50 | 3.1 | 283 | Pos | 10 | 15 | CRD |
M | 67 | Colon | 40 | No | 3 | 8 | 10.6 | 497 | Neg | 11 | 11 | CRD |
M | 67 | Colon | 22 | No | 1 | 60 | 134 | 158 | Neg | 3 | AWD | |
M | 68 | Colon | 41 | No | 1 | 45 | ND | 297 | Neg | 1 | AWD | |
M | 72 | Colon | 25 | No | 1 | 18 | 2.4 | 397 | Pos | FREE | ||
M | 74 | Rectum | 4 | Yes | 4 | 32 | 3.4 | 583 | Pos | FREE | ||
M | 81 | Colon | 8 | No | 1 | 22 | ND | 345 | Pos | FREE |
Clinical, histopathological and laboratory data on the eighteen patients with liver metastasis from CRC that were included in the study. Observation time was 18 months before outcome was assessed and classified as follows: CRD cancer-related death, NRCD non-cancer-related death, AWD alive with disease, FREE disease free at follow-ups. ND: CEA, PGE2 and HLA-A2 not determined in given patient. aDenotes inoperable patient; size and number of metastases were estimated by radiography